Targeting BRAF‐Mutant Non‐Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy

This review provides a comprehensive overview of the clinical characteristics and prognostic implications for patients with BRAF‐mutant non‐small cell lung cancer and discusses therapeutic strategies that leverage experience from BRAF‐mutant metastatic melanoma. Practical considerations for oncologists are discussed, including considerations for molecular profiling and management of potential toxicities associated with targeted agents.

[1]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[2]  M Hummel,et al.  A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance , 2015, Cancer Gene Therapy.

[3]  Jeffrey W. Clark,et al.  NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[4]  A. King,et al.  Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions , 2013, PloS one.

[5]  O. Rath,et al.  MAP kinase signalling pathways in cancer , 2007, Oncogene.

[6]  A. Yoshizawa,et al.  Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer. , 2011, Anticancer research.

[7]  H. Groen,et al.  Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. , 2016, The Lancet. Oncology.

[8]  Antonio Marchetti,et al.  Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Dirk Schadendorf,et al.  Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .

[10]  Lin Huan,et al.  Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer , 2010 .

[11]  G. Bollag,et al.  Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer , 2016, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Y. Ishikawa,et al.  EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset , 2009, Modern Pathology.

[13]  P. Ascierto,et al.  Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.

[14]  R. Doebele,et al.  A framework for understanding and targeting residual disease in oncogene-driven solid cancers , 2016, Nature Medicine.

[15]  L. Layfield,et al.  Lack of BRAF Activating Mutations in Prostate Adenocarcinoma: A Study of 93 Cases , 2009, Applied immunohistochemistry & molecular morphology : AIMM.

[16]  BRAF inhibitor activity in V600R metastatic melanoma--response. , 2013, European journal of cancer.

[17]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[18]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.

[19]  C. Belani,et al.  Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer , 2015, PloS one.

[20]  Jeanne Shen,et al.  Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.

[21]  N. Girard,et al.  Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations. , 2016, Lung cancer.

[22]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[23]  Mari Mino-Kenudson,et al.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. , 2012, Cancer discovery.

[24]  A. Bryce,et al.  Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma , 2015, Cureus.

[25]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[26]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[27]  D. Schadendorf,et al.  BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management. , 2014, Chinese clinical oncology.

[28]  L. Haydu,et al.  Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma , 2014, Melanoma research.

[29]  M. Ladanyi,et al.  Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[30]  A. Sihoe,et al.  The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS , 2009, Cancer.

[31]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[32]  M. Ladanyi,et al.  Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium , 2015, Cancer.

[33]  Sourav Bandyopadhyay,et al.  Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer , 2014, Proceedings of the National Academy of Sciences.

[34]  E. Nexo,et al.  Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays , 2014, BMC Cancer.

[35]  W. Sellers,et al.  Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance , 2013, Nature.

[36]  William Pao,et al.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.

[37]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[38]  J. Utikal,et al.  Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.

[39]  Bastien Cabarrou,et al.  Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[40]  M. Ladanyi,et al.  Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Marius Ilie,et al.  Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? , 2014, Annals of translational medicine.

[42]  Jean Mosser,et al.  Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) , 2016, The Lancet.

[43]  V. Sondak,et al.  Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy , 2010, British Journal of Cancer.

[44]  I. Wistuba,et al.  Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations. , 2015, The oncologist.

[45]  N. Myall,et al.  Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene. , 2016, Clinical Lung Cancer.

[46]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[47]  Jeffrey W. Clark,et al.  Crizotinib in ROS 1-Rearranged Non – Small-Cell Lung Cancer , 2014 .

[48]  T. Kohno,et al.  Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  B. Neyns,et al.  Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors , 2016, Journal of Translational Medicine.

[50]  Todd R. Golub,et al.  BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.

[51]  Tae Min Kim,et al.  Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[52]  R. Dummer,et al.  Ultraviolet A and photosensitivity during vemurafenib therapy. , 2012, The New England journal of medicine.

[53]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[54]  J. Utikal,et al.  Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial , 2015, The Lancet.

[55]  Anil Vachani,et al.  Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA , 2016, Clinical Cancer Research.

[56]  J. Blay,et al.  Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. , 2015, The New England journal of medicine.

[57]  Matthew Wongchenko,et al.  Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. , 2016, The Lancet. Oncology.

[58]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[59]  D. English,et al.  Ethnicity and Risk for Colorectal Cancers Showing Somatic BRAF V600E Mutation or CpG Island Methylator Phenotype , 2008, Cancer Epidemiology Biomarkers & Prevention.

[60]  S. Welsh,et al.  Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma , 2015, Therapeutic advances in medical oncology.

[61]  L. Decoster,et al.  Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib , 2016, Oncotarget.

[62]  Kyung Chul Moon,et al.  BRAF and KRAS mutations in prostatic adenocarcinoma , 2006, International journal of cancer.

[63]  H. Sasaki,et al.  Uncommon V599E BRAF mutations in Japanese patients with lung cancer. , 2006, The Journal of surgical research.

[64]  G. Sauter,et al.  Activating BRAF gene mutations are uncommon in hormone refractory prostate cancer in Caucasian patients. , 2010, Oncology letters.

[65]  Tae Min Kim,et al.  An open-label phase 2 trial of dabrafenib plus trametinib in patients with previously treated BRAF V600E–mutant metastatic non-small cell lung cancer , 2016 .

[66]  A. Gemma,et al.  F1000 highlights , 2010 .

[67]  J. Gray,et al.  BRAF V600E mutations: a series of case reports in patients with non-small cell lung cancer. , 2015, Cancer genetics.

[68]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.